Background--Patients receiving oral anticoagulation in addition to dual-antiplatelet therapy are known to be at high risk for bleeding events; thus, the selection of a drug-eluting stent (DES) versus a bare metal stent (BMS) can have important implications for patients with atrial fibrillation (AF) presenting with acute myocardial infarction (MI).
T he management of antiplatelet and anticoagulant medications among patients with atrial fibrillation (AF) presenting with acute myocardial infarction (MI) can be challenging. Guidelines recommend 1 year of dual-antiplatelet therapy (DAPT) for patients following acute MI; however, for patients with AF requiring percutaneous coronary intervention (PCI), the optimal antithrombotic strategy is unclear, and an important factor in determining DAPT duration may be the type of stent that is implanted during the procedure. Drug-eluting stents (DESs) have traditionally been thought to have a lower risk of longer term, in-stent restenosis at a cost of increased stent-thrombosis risk for a longer period of time following implantation, although more recent data suggest newer generation DESs may be safer. [1] [2] [3] Although current American College of Cardiology (ACC) and American Heart Association (AHA) guidelines recommend DAPT for at least 12 months following acute coronary syndrome, 4 minimum duration of DAPT may be driven in part by stent type in clinical practice, with at least 6 months for patients with a DES as opposed to 30 days for patients with a bare metal stent (BMS); recent meta-analyses have suggested that a shorter duration of DAPT with DES may be reasonable. 5, 6 It is well known that triple therapy with DAPT and an oral anticoagulant (OAC) increases bleeding risk, and clinicians must determine the most appropriate strategy to balance thrombotic complications after PCI with this increased bleeding risk. There is significant heterogeneity in the professional guidance regarding stent-type implantation among patients with AF. The ACC/AHA ST-segment-elevation MI guidelines note a class 3 recommendation (harm) in using DESs in patients unable to comply with long-term DAPT, 7 and this may be a consideration in patients requiring long-term OAC. A North American consensus document specifically recommends avoiding DES use in patients with AF and high bleeding risk. 8 The 2014 ACC/AHA AF guidelines allow for consideration of a BMS to minimize duration of DAPT (class 2b, level of evidence C). 9 Although previous guidance from the European Society of Cardiology 10, 11 suggested that DESs should be avoided, more recent guidance suggests that current-generation DESs may be preferred. 11 The latest AF guidelines, however, provide recommendations only on antithrombotic therapy strategy, not stent-type selection. 12 Using the NCDR â (National Cardiovascular Data Registry) ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry-Get With the Guidelines (ACTION Registry-GWTG), we sought to evaluate temporal trends and hospital variation in the use of DESs among patients with a history of AF who presented with acute MI. We also sought to evaluate patterns of DES use in patients stratified by stroke and bleeding risk. In a subset of patients with linkage data from Medicare claims, we evaluated 1-year rates of mortality, ischemia, and bleeding outcomes for patients receiving a DES or a BMS.
Methods Data Source and Study Population
The ACTION Registry-GWTG is the largest quality improvement registry of acute MI in the United States and captures detailed clinical data on consecutive patients presenting with acute MI treated at each participating hospital. Details of the design and conduct of this registry have been described previously, 13, 14 and the registry is regularly and rigorously audited for data completeness and accuracy. 15 Participation in the registry was approved by each hospital's institutional review board, and because data are collected without individual patient identifiers, the requirement for individual informed consent was waived. Between July 1, 2008, and March 31, 2014, we identified 554 214 eligible patients presenting with acute MI at 780 ACTION Registry-GWTG sites in the United States. We excluded patients who presented at hospitals without PCI or coronary artery bypass grafting (CABG) capabilities (n=15 494). We then excluded patients who did not undergo PCI with stent placement (n=227 465) and patients for whom the information necessary to calculate the CHA 2 DS 2 -VASc or modified ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) score was missing (n=3928). We also excluded patients without a history of AF or flutter (n=292 900) within the 2 weeks before presentation, as captured on the data collection form, yielding a final study population of 14 427 patients at 652 sites nationwide.
To obtain longitudinal outcomes, patients aged ≥65 years in this registry were linked with Medicare claims data using 5 indirect identifiers in combination (date of birth, sex, hospital identifier, date of admission, date of discharge) using previously described methodology. 16 Linked patients were those discharged alive with Medicare Parts A and B fee-forservice eligibility at discharge who also had Medicare Parts A and B fee eligibility for the 12 months before the index hospitalization. In addition, because the latest available linkage records available were through 2012, we focused on patients who were discharged before 2011 to allow at least 1 year for follow-up. After exclusions, 2844 patients with AF presenting with acute MI at 379 sites were evaluated for 1-year outcomes (Figure 1 ).
Outcomes and Definitions
The presence of AF or flutter within the 2 weeks before the index hospitalization for acute MI was denoted on the ACTION Registry-GWTG data collection form, as was the type of stent (DES versus BMS) used during the index PCI procedure. Patients receiving both DES and BMS were classified as DES patients for this analysis. We calculated the CHA 2 DS 2 -VASc score using the data elements from the data collection form;
Clinical Perspective
What Is New?
• This study demonstrates significant practice variation in stent selection among atrial fibrillation patients with acute myocardial infarction undergoing percutaneous coronary intervention, with an increasing proportion of patients undergoing drug-eluting stent placement.
What Are the Clinical Implications?
• The type of implanted stent may have significant implications with respect to the type and duration of antiplatelet and anticoagulant therapies in this high-risk population, especially in patients at high ischemic and/or bleeding risk.
for this analysis, the presence of vascular disease was defined as having a history of prior MI, peripheral artery disease, prior PCI, or prior CABG. We calculated a modified ATRIA score that assigned points for anemia (hemoglobin <13 for men or <12 for women, 3 points), severe renal disease (glomerular filtration rate <30 or dialysis, 3 points), age ≥75 years (2 points), and hypertension (1 point). The ATRIA score assigns 1 point to history of prior bleeding, which was not captured in this registry; as such, the maximum score in this modified ATRIA model is 9 points, compared with 10 points from the actual ATRIA model. For linked patients with longitudinal data, we evaluated 4 outcomes: (1) a composite end point including all-cause mortality and rehospitalization for MI or stroke; (2) readmission for stroke; (3) readmission for repeat revascularization; and (4) readmission for major bleeding. Readmission for MI, stroke, repeat revascularization, and major bleeding were defined using the primary International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis code and procedure codes for subsequent hospitalizations after the index hospitalization (list of diagnosis codes is shown in Table S1 ). All-cause mortality was ascertained from the Medicare denominator file.
Statistical Analysis
We compared baseline demographic, presentation, in-hospital, and discharge characteristics for patients receiving a DES versus a BMS during the index presentation. Continuous variables are expressed as median values with 25th and 75th percentiles, whereas categorical values are presented as percentages. Pearson v 2 tests were used to compare categorical variables, and Wilcoxon rank sum tests were used to compare continuous variables between 2 groups. Temporal trends in DES use were plotted semiyearly, and the Cochran-Armitage trend test with a 2-sided P-value was used to test for significance. As a comparator, we evaluated DES use among patients meeting all other inclusion and exclusion criteria except for the presence of AF or flutter to demonstrate the temporal trend of DES use among non-AF patients. We identified site-level variation associated with the use of DES but excluded sites with <10 eligible patients (n=256 hospitals) during the study period. To evaluate for significant practice-level variation, we included hospital as a random effect in a generalized linear mixed model for DES implantation. The variance component was tested against 0 to evaluate the hypothesis that hospitals differ in their rates of DESs used. To evaluate whether hospital characteristics (including hospital type: PCI only versus surgery, academic centers, number of hospital beds, hospital region) were associated with an increased likelihood of DES implantation, we divided the remaining 396 sites into tertiles by proportion of DES use and summarized hospital characteristics by tertiles of DES use.
Using the calculated CHA 2 DS 2 -VASc and modified ATRIA scores, we divided patients by predicted stroke and bleeding risk, respectively. A CHA 2 DS 2 -VASc score of ≥2 denoted high stroke risk, and a modified ATRIA score ≥4 denoted high bleeding risk. Rates of DES implantation were compared for patients with high versus low ischemic and bleeding risk.
In the linked analysis, unadjusted rates of the 1-year composite end point of mortality and readmission for MI or stroke were estimated using the product limit method (Kaplan-Meier). The failure curves between patients with DESs and those with BMSs were compared using the log-rank test. The unadjusted cumulative incidence of each nonfatal adverse outcome of interest (readmission for stroke, readmission for repeat revascularization, readmission for major bleeding) was compared using Gray's method to account for mortality as a competing risk for readmission. 17, 18 We then used multivariable Cox proportional hazards models to compare risk-adjusted outcomes between patients receiving a DES versus a BMS. For the readmission outcomes within 1 year of discharge, follow-up was censored at last follow-up or at death, if occurring before the event of interest. The resulting hazard ratios (HRs) estimated the cause-specific effect among patients still alive and at risk. Robust standard errors were used to adjust for within-hospital clustering, as patients treated at the same hospital tended to have more similar responses relative to patients treated at other hospitals. Outcomes were adjusted for the following variables based on the previously validated ACTION Registry-GWTG mortality risk model 19 Statistical significance was defined as P<0.05. All analyses were performed by the NCDR data analysis center at the Duke Clinical Research Institute using SAS software (versions 9.3 and 9.4).
Results
After exclusions, we identified 14 427 patients with a history of AF presenting with acute MI who underwent PCI (Figure 1) . Overall, DESs were used in 8494 (58.9%) patients. The proportion of patients receiving a DES increased from 47.1% in 2008 to 67.9% in 2014 (P<0.001). For comparison, among patients in the ACTION Registry-GWTG who met other inclusion and exclusion criteria but did not have AF (n=292 and n=900, respectively), the overall rate of DES use was 70.4%, increasing from 58.9% in 2008 to 79.1% in 2014 (Figure 2 ).
Patients receiving a DES were younger (median age 72 versus 75 years, P<0.001) and less often female. They more often had a history of diabetes mellitus and prior MI and revascularization with either PCI or CABG but less often had a history of prior stroke. Prior to admission, DES patients were more often treated with aspirin and a P2Y 12 inhibitor but less often treated with warfarin than BMS patients; however, 24.8% of patients receiving a DES were on warfarin at home. On admission, patients eventually receiving a DES less often presented with ST-segment elevation MI, heart failure, or cardiogenic shock on admission (Table 1) . Table 2 describes in-hospital characteristics of patients receiving a DES versus a BMS. Patients receiving a DES had smaller infarct size, as measured by peak troponin, and were less likely to develop heart failure, cardiogenic shock, stroke, or major bleeding (all P<0.001) compared with patients receiving a BMS. They were also less likely to receive blood transfusion (P<0.001). Differences were statistically significant but clinically modest.
There were similar rates of discharge on DAPT between patients receiving a DES versus a BMS (Table 3) . DES patients were more likely to be discharged on a higher potency P2Y 12 inhibitor such as prasugrel or ticagrelor (17.0% versus 9.6%, P<0.001). Only 34.0% of patients were discharged on warfarin, with lower rates among patients receiving DESs than BMSs (30.8% versus 39.0%, P<0.001).
After excluding hospitals with <10 eligible patients during the study period (256 hospitals), we evaluated hospital-level variation in DES use. Figure 3 demonstrates the hospital level of percentage of DES use with an exact 95% binomial confidence interval (CI) for the remaining 396 hospitals rankordered by percentage of DES use. There was significant hospital level variation in the proportion of DESs used, with the median hospital utilizing DESs in 60.2% of patients (interquartile range: 50.0-73.7%) but ranging from 0% to 100%. Hospitals in the highest tertile of DES use had modestly fewer beds and were less likely to have CABG capability (Table 4) .
We examined DES selection among patients classified as high versus low predicted bleeding and stroke risk. The median modified ATRIA score was 3 (interquartile range: 1-4). Overall, 4595 (31.9%) patients were at high bleeding risk, classified by a modified ATRIA score ≥4. Among these patients, 2573 (56.0%) underwent DES placement, whereas 60.2% of patients at low bleeding risk (modified ATRIA score <4) underwent DES placement. The median CHA 2 DS 2 -VASc score in our study population was 4 (interquartile range: 3-5); 12 812 patients (88.8%) had a CHA 2 DS 2 -VASc score ≥2. Among these patients, 7492 (58.5%) underwent DES placement, whereas among the 1615 patients at low stroke risk, 62.0% received a DES (Figure 4 ). Among a subset of patients with Medicare-linked data (n=2844), the unadjusted cumulative incidence of the composite outcomes of all-cause mortality and readmission for MI or stroke was 22.9% among DES patients versus 26.9% among BMS patients (P=0.02), although this difference was attenuated after multivariable adjustment (adjusted HR: 0.88; 95% CI, 0.76-1.03). Rates of mortality were lower in patients receiving a DES (16.1% versus 20.9%, P=0.001) but were similar after multivariable adjustment. Rates of readmission for stroke at 1 year were similar between DES and BMS patients before and after multivariable adjustment (2.9% versus 2.6%, P=0.69; adjusted HR: 1.14; 95% CI, 0.70-1.88), as were rates of readmission for repeat revascularization (10.8% versus 9.0%, P=0.13; adjusted HR: 1.08; 95% CI, 0.84-1.39) and readmission for major bleeding (9.7% versus 9.0%, P=0.55; adjusted HR: 1.09; 95% CI, 0.87-1.36; Table 5 ). Cumulative incidence curves are shown in Figure S1 .
We performed a sensitivity analysis to evaluate whether outcomes differed across generation of DES by dividing our study period into 2 periods when first-generation DESs (2008-2010) and second-generation DESs (2011-2014) were more broadly used. Our results were broadly consistent with the primary analysis (P=0.66, interaction for composite outcome). These results are shown in Table S1 .
Discussion
Our study represents the first national examination of stent selection among patients with a history of AF presenting with acute MI. The rate of DES implantation has increased significantly over time, with more than two-thirds of AF patients now receiving a DES during their hospitalization for acute MI. However, there is significant hospital-level variation in the rate of DES implantation among MI patients, and, paradoxically, those at highest risk of stroke and bleeding were most likely to receive a DES. After adjusting for patient and presentation characteristics, there were no observed differences in adverse cardiovascular or bleeding outcomes between patients receiving a DES versus a BMS. DESs have been shown to decrease the risk of in-stent restenosis by inhibiting neointimal hyperplasia compared with BMS, but longer duration DAPT is generally required to mitigate the increased risk of in-stent thrombosis, particularly in older generation DESs. Although current guidelines ACC/AHA guidelines still recommend 12 months of DAPT following DES placement but 30 days for patients treated with a BMS. This is different from the current European guidelines, which tailor antithrombotic strategy to bleeding risk and favor short-duration triple therapy in patients at high risk of bleeding. Although the current North American risk. This figure reports the percentage of DES use stratified by predicted stroke and bleeding risk. Low stroke risk is defined as a CHA 2 DS 2 -VASc score <2, and a low modified ATRIA score is defined as <4.
consensus guidelines recommend avoiding DESs in patients who are at high risk of bleeding or unable to comply with DAPT, European guidance now suggests DES placement for all patients, coupled with shorter duration DAPT; no randomized data support this strategy.
We found that this lack of clear evidence and the conflicting guidelines statements led to considerable variability in community practice. Nevertheless, we also found an overall trend toward greater use of DESs among AF patients over time. There may be a number of possible explanations for these trends. First, DES technology has improved during the study period, and coupled with refinements in stent-deployment technologies, current-generation DESs may have a similar or lower rate of stent thrombosis than BMSs. 1, 2, [24] [25] [26] More recently, the Norwegian Coronary Stent Trial (NORS-TENT) demonstrated a slightly lower rate of stent thrombosis with DESs compared with BMSs, although overall rates of stent thrombosis were very low. 3 In addition, a number of studies have demonstrated that shorter duration of DAPT may not increase overall ischemic risk in this patient population. 22, 23 Therefore, investigators may feel more comfortable using DESs with a shorter duration of DAPT, particularly in patients at high risk of bleeding. The substantial practice variation that we observed in this study, however, suggests that the evidence base for stent selection in this high-risk population remains ill-defined, and there is no clear consensus about the benefits of a DES versus a BMS in patients currently on an OAC. Despite current guidelines recommending risk stratification, particularly for bleeding, when selecting stent type, we report overall modest differences in DES use across the strata of bleeding and stroke risk, with DESs used more frequently than not among patients at increased risk of bleeding. For patients at high stroke risk requiring lifelong anticoagulation, we felt that further risk stratification by bleeding risk may affect DES selection, but the overall difference in DES use was modest between patients with high versus low bleeding risk. Conversely, DES use is only slightly higher among patients at low stroke risk who likely do not require anticoagulation, highlighting the lack of overall risk assessment prior to stent selection.
Our study also highlights the implications for DES use with respect to antithrombotic therapy strategy at discharge. In our study, there was almost universal discharge on DAPT. Although most patients were discharged on aspirin and clopidogrel, there was a small but sizeable proportion of patients discharged on more potent P2Y 12 inhibitors despite a class 3 recommendation for their use among patients requiring an OAC. This suggests that these patients may be exposed to higher bleeding risk by combining a more potent antiplatelet agent with an OAC or may be subjected to downstream switching as the P2Y 12 inhibitor is transitioned to clopidogrel once an OAC is added. In addition, a minority of patients were discharged on warfarin, regardless of the type of stent implanted. This result is concordant with a prior analysis from the DANISH Registry that analyzed antithrombotic therapy selection for AF patients with an indication for DAPT, although that analysis also did not capture information on stent-type selection. 27 Although our study does not capture discharge on novel OAC agents, none are currently recommended for use in combination with DAPT. Our analysis suggests either that providers may be underestimating stroke risk in AF patients by implanting DESs and discharging patients without OACs or that the operators understand that the daily risk of stroke, even in high-risk patients, is low enough that treatment with DAPT for 1 month followed by reinstitution of OAC may not increase stroke risk. A number of trials are currently evaluating antithrombotic strategy among patients with AF undergoing PCI [28] [29] [30] ; however, because all of these trials allow for stent selection at the discretion of the investigator, information gleaned about the effect of stent selection in optimizing patient outcomes in this population may be limited. Our study must be considered in light of a number of important limitations. First, we did not capture individual provider rationale for stent selection. We also retrospectively calculated the CHA 2 DS 2 -VASc and the modified ATRIA scores; because we did not capture a history of prior hemorrhage, the maximum ATRIA score is 9 instead of 10. The lack of data on prior hemorrhage may affect the overall validity of the ATRIA score. Although it is possible that operators may have used another method of risk stratification, both the CHA 2 DS 2 -VASc and ATRIA scores have been well validated to accurately stratify stroke and bleeding risk in patients with AF. Next, we did not capture information on any of the novel OACs (dabigatran, rivaroxaban, apixaban, edoxaban); however, none are currently indicated for use in this patient population. In addition, because this information is not captured, the overall proportion of patients on an OAC coupled with DAPT is likely higher than what we reported in this study. Moreover, the ACTION Registry-GWTG does not capture information regarding stent generation. The second-generation DESs, which were predominantly used during most of the study period for this analysis, have a more favorable safety profile than firstgeneration DESs. Finally, because this analysis is observational, we are unable to draw causal inferences from these results, and we cannot exclude the possibility of unmeasured confounding.
Conclusions
Among AF patients presenting with acute MI, the use of DES has increased over time with substantial hospital-level variation. Paradoxically, patients with the highest risk of stroke and bleeding were most likely to received a DES. After multivariable adjustment, we observed no differences in rates of adverse cardiovascular or bleeding outcomes between patients receiving a DES versus a BMS. 
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